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Background: Azithromycin is widely used as an immunomodulatory agent in the treatment of cystic ﬁbrosis with previous literature documenting
improvements in lung function and a reduction in infective exacerbations. The maximal study period in adults has been six months.
Methods: 81 adult patients taking continuous azithromycin were retrospectively identiﬁed. Percentage predicted FEV1 and courses of intravenous
antibiotics were examined at yearly intervals two years prior to and two years after azithromycin initiation.
Results: FEV1 deteriorated in the two years before starting azithromycin by a mean of 2.02% per year. In the year following initiation, FEV1
increased by 1.15% (P=0.01). However, a mean 2.58% reduction was observed in year two. There was no statistically signiﬁcant effect on courses
of intravenous antibiotics.
Conclusions: Azithromycin resulted in an improved FEV1 at year one. This effect was not sustained beyond the ﬁrst year of treatment.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Azithromycin; Lung function1. Introduction
Cystic fibrosis is an autosomal recessive disease, characterised
by abnormal regulation of chloride transport across epithelial
cells. Progressive lung disease results in the majority of patients
ultimately dying from respiratory failure. Chronic bronchial
infection with exaggerated inflammation is thought to initiate
and potentiate lung destruction. Current treatment of cystic
fibrosis lung disease includes antibiotics, mucolytics and anti-
inflammatory agents (Murry et al., 1999). Azithromycin has been
introduced as one such immunomodulatory agent.
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doi:10.1016/j.jcf.2012.05.010disease including colonisation with Pseudomonas aeruginosa
and chronic suppurative lung disease. Erythromycin, a macrolide
antibiotic not regarded to possess direct activity against
P. aeruginosa, was demonstrated to reduce mortality (Nagai et
al., 1991). This led to trials of macrolide antibiotics in populations
with cystic fibrosis. The macrolide antibiotic azithromycin
displays a longer duration of action and superior tissue penetration
than erythromycin (Kucers, Crowe, Grayson, & Hoy, 1997).
Following encouraging results from a single institution case series
(Jaffe, Francis, Rosenthal, & Bush, 1998), azithromycin has been
evaluated in randomised controlled trials. These have demon-
strated a small but significant improvement in respiratory function
and a reduction in infective exacerbations (Wolter et al., 2002;
Equi, Balfour-Lynn, Bush, & Rosenthal, 2002; Saiman,Marshall,
Mayer-Hamblett, et al., 2003). These effects were persistent when
combined in the Cochrane Groupmeta-analysis (Southern, Baker,
& Solis-Moya, 2011). Azithromycin has now become established
in the treatment of cystic fibrosis patients. However, the longestby Elsevier B.V. All rights reserved.
Table 1
Clinical characteristics of study population (n=81).
Clinical characteristics Mean (SD)
Male (percentage) 39 (48.1)
Age, yrs 31.01 (9.16)
Height, meters 1.67 (0.08)
Weight, kilograms 59.8 (9.41)
FEV1% predicted baseline 44.46 (19.02)
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children and adolescents (Saiman et al., 2003; Clement et al.,
2006).
This retrospective case series investigates the effects of
azithromycin on lung function and infective exacerbation rates in a
“real life” adult population over a 24month period. It recognises
the limitations associatedwith retrospective investigation including
the lack of a placebo group and a standardised selection protocol.
2. Methods
The study was undertaken at the adult cystic fibrosis
department at the Royal Brompton Hospital, London, UK.
The electronic database was examined for patients prescribed
azithromycin as an immunomodulatory agent in 2005. The
database had ethical approval for anonymised data to be
analysed. Individual patients had given written consent for their
data to be incorporated into the database. One hundred and
sixty five patients were initially identified and selected using
inclusion and exclusion criteria (Fig. 1). Inclusion criteria were
continuous azithromycin treatment having started at 18years of
age or greater while under the care of our clinic. Exclusion criteria
were commencement or cessation of RhDNAse, nebulised
antibiotics or mucolytic therapy during the study period; lung
transplantation prior to or during study period and death. Patients
with changes to other prescribed treatments were excluded to
remove the possibility that differences observed could be
attributable to other medications. All patients colonised with
Staphylococcus aureus are routinely prescribed flucloxacillin.
The time for initiation of azithromycin ranged from 24.09.2001 to
15.11.2005.
Data was collected from the retrospective examination of
hospital medical records. Over a four year study period
percentage of predicted forced expiratory volume in 1 second
(FEV1) and the number of courses of intravenous antibiotics
were documented at yearly intervals (two years prior to and two
years after initiation of azithromycin). The date of the first
prescription was taken as the introductory time point to the study.
If data was unavailable at the scheduled interval, it was recordedFig. 1. Study flow diagram.within +/−3months. If a patient was clinically unstable (defined
as additional antibiotic therapy for respiratory infection),
information was collected when the patient had stabilised within
+/−3months (when any additional antibiotic therapy had ceased).
If data was unavailable within this time period theywere excluded
from the study. Dosages of azithromycin were documented.3. Statistical analysis
The primary study outcome was changed in FEV1%
predicted at the end of the first and second year of treatment.
Results were analysed on a cumulative and sub‐group basis
(azithromycin dose). All continuous data were examined for
normal distribution. This was reported as a mean+/−standard
deviation (SD). The mean FEV1 percentage predicted was
analysed on a sub-group basis via paired T‐tests. Categorical data
is presented as median+/− interquartile range. The differences
between the numbers of antibiotic courses each year were
analysed using a paired T-test. All statistics were calculated using
Stata (Statacorp, College Station, Texas, US).4. Results
Fig. 1 illustrates patient identification and selection.
Table 1 shows the clinical characteristics of the patients. The
mean age was 31.01+/−9.16years, 39 (48.1%) were male and
42 (51.9%) were female.Azithromycin dose (percentage)
500mg daily 51 (63.0)
500mg 3 times weekly 24 (29.6)
250mg od 5 (6.2)
250mg 3 times weekly 1 (1.2)
Sputum bacteriology prior to initiation (percentage)
Pseudomonas aeruginosa 67 (82.7)
Methicillin sensitive Staphylococcus aureus 32 (40.0)
Methicillin resistant Staphylococcus aureus 2 (2.5)
Burkholderia species 2 (2.5)
No sputum 3 (3.7)
Sputum bacteriology post study period (percentage)
Pseudomonas aeruginosa 68 (84.0)
Methicillin sensitive Staphylococcus aureus 26 (32.1)
Methicillin resistant Staphylococcus aureus 5 (6.2)
Burkholderia species 3 (3.7)
No sputum 1 (1.2)
Abbreviations: FEV1, Forced expiratory volume in one second.
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Fig. 2 shows the FEV1% predicted both before and after
azithromycin. FEV1% predicted deteriorated in the two years
prior to starting azithromycin by a mean of 2.02% per year. In
the year following initiation, FEV1 increased by a mean 1.15%.
The mean change in FEV1% predicted for the year before and
after azithromycin therapy was compared, and this was
significant (P=0.01). However, a mean 2.58% decline was
observed into year two (Fig. 2). When the 5 patients taking
250mg daily and the single patient on 250mg 3 times weekly
were removed from the analysis, the results remained statistically
significant.
On a sub‐group analysis of 500mg daily and 500mg 3 times
weekly, the decrease in FEV1% predicted in the year before
azithromycin therapy compared to the year after was not
significant (500mg daily P=0.06; 500mg 3 times weekly P=
0.09).
4.2. Courses of IV antibiotics
For the purpose of statistical analysis the numbers of courses
of intravenous antibiotics were treated as a discrete continuous
variable. There was no significant difference between the time
periods pre and post azithromycin for the number of courses of
antibiotics. No adverse events attributable to azithromycin were
reported from this cohort during the 2years after azithromycin
initiation. There were no new non-tuberculous mycobacterium
isolates found in the cohort.
5. Discussion
Five previous randomised controlled trials have investigated
azithromycin and cystic fibrosis. These are summarised in
Table 2. The present study demonstrated a statistically significant
improvement in FEV1 in the first year after the introduction of
azithromycin. Three prior studies have similarly shown a
statistically significant increase in FEV1 when compared to
placebo, the magnitude of which is comparable to our study.
(Wolter et al., 2002; Equi et al., 2002; Saiman et al., 2003). TheFig. 2. Mean FEV1% predicted total population before and after azithromycin.two randomised controlled trials to date that did not exhibit this
effect studied pediatric populations with relatively preserved lung
function who were predominately without pseudomonal infection
(Clement et al., 2006; Saiman, Anstead, Mayer-Hamblett, et al.,
2010).
The cohort within the present study differs to that of
previous trial populations. The mean age in the current study
was 31.0+/−9.2years, reflecting a more elderly population than
in any of the preceding randomised studies. The cohort also had
lower baseline lung function (mean FEV1% predicted of
44.5+/−19.2). The patients in this study had a more rapidly
declining FEV1 and a lower lung function than the mean for
patients attending clinic in our centre. It may be that patients
selected for azithromycin in the present study had advanced and
more progressive disease.
Despite improvement in lung function in year one, this effect
was not sustained into the second year after azithromycin
therapy. The rate of decline in lung function in the second year
following azithromycin therapy was similar to that of the years
prior to the introduction of azithromycin.
The longest previous study was twelve months in duration
(Clement et al., 2006). However most other randomised controlled
trials have been markedly shorter. An open label uncontrolled
prospective studywithin a pediatric population was consistent with
our study with the authors finding that the initial improvement in
FEV1% at one year was not maintained into years two and three
(Tramper-Stranders, Wolfs, Fleer, Kimpen, & van der Ent,
2007). Our results do not support the hypothesis of azithromycin
possessing a prolonged immunomodulatory action.
The present study found no relationship between the initiation
of azithromycin and the number of courses of intravenous
antibiotics. This concurs with the majority of the previous
literature. Although some studies have found trends towards a
reduction in the courses of intravenous antibiotics following
azithromycin (Saiman et al., 2003; Clement et al., 2006), only
one noted a significant reduction (Wolter et al., 2002). One
explanation for finding no reduction may be that the patients in
the present study were an older population with more advanced
lung disease.
The optimal dosing regimen of azithromycin is yet to be
established. The most frequently prescribed dose in this study
was 500mg daily. Within previous literature the most prevalent
dose was 500mg 3 times weekly (Wolter et al., 2002; Saiman et
al., 2003; Clement et al., 2006; Saiman et al., 2010). However,
Equi et al. demonstrated efficacy within a pediatric population
utilizing a dose of 500mg daily (Equi et al., 2002).
The retrospective design of the current study has limitations.
The lack of a placebo‐controlled groups means that the
improvement in FEV1 seen after year one could be due to the
placebo effect. In addition, azithromycin was not initiated in a
systemic manner and may have been precipitated by a
deterioration in lung function, even after routine changes in
treatment. Therefore the results seen in year one may also be
explained by reversion to the mean. Patients who died or who
were transplanted were excluded from the study as they did not
complete the two years of therapy required for inclusion and
analysis. This may have selected patients who responded better
Table 2
Summary of randomised placebo‐controlled trials of azithromycin in patients with cystic fibrosis.
Study Study design N Age (Y) Microbiology Dose Baseline
lung
function
Duration Outcome — lung function Outcome — exacerbation
rates
Outcome —
other effects
Wolter et al.
(2002)
Two centre
randomised
double-blind
placebo-
controlled trial
60 Mean 27.9
(SD 6.4)
83.3% infected with
P aeruginosa. 6.7%
infected with
B cepacia.
250mg OD Mean
FEV1%
predicted
56.6%
(SD+/−
22.3)
3months 2.95% increase in FEV1%
pred in AZM vs 0.91%
decrease in placebo at
3months. Mean difference
3.62% (95% CI 7.71 to
0.13, P=0.047) averaged from
3 separate monthly intervals.
Reduced courses of IV abx
in AZM group (0.37 vs 1.13,
P=0.016)
Improved
quality of life
scores (P=0.035)
Equi et al.
(2002)
Two centre
randomised
double-blind
placebo‐
controlled
crossover trial
41 Median 13.8
(range 8.1–18.6)
51.2% infected with
P aeruginosa.
B cepacia
carriers excluded.
b40kg 250mg od;
weight≥40kg
500mg od
Mean
FEV1%
predicted
60%
(SD+/−
13)
6months
then
crossover
Increased FEV1% pred in AZM
group. Median relative difference
AZM vs placebo at 2, 4 and
6months 5.4% (95%
CI 0.8–10.5).
No difference in IV abx or
pulmonary exacerbations.
No difference
between dosage
regimens
Saiman et al.
(2003)
Multicentre
randomised
double-blind
placebo-
controlled trial
185 Mean 20.4
(SD 8.3)
All infected with
P aeruginosa.
B cepacia
excluded.
b40kg 250mg
3 times weekly;
≥40kg 500mg
3 times weekly
Mean
FEV1%
predicted
69.5%
(SD+/−
22.5)
6months 4.4% relative increase FEV1%
pred AZM vs 1.8% decline
placebo. Mean difference
FEV1% pred at 168days
6.2% (95% CI 2.6–9.8,
P=0.001). Change not
sustained after AZM
withdrawal.
Reduction in exacerbations,
hazard ratio 0.65 (95% CI
0.44–0.95, P=.03).
Non-significant trend to
reduced IV abx.
Average 0.7kg
weight increase
(95% CI 0.1–
1.4kg, P=0.02)
Clement et al.
2006
Multicentre
randomised
double-blind
placebo-
controlled trial
82 Mean 11.0
(SD 3.3)
23.2% infected with
P aeruginosa.
b40kg 250mg
3 times weekly;
≥40kg 500mg
3 times weekly
Mean
FEV1%
predicted
85.5%
(SD+/−
22)
12months No significant change
in FEV1% pred.
Reduction in pulmonary
exacerbations, rate ratio
0.50 (95% CI 0.32–0.79,
Pb0.005). Non-significant
trend to reduced IV abx.
Reduction oral abx, rate
ratio 0.55 (95% CI 0.36
to 0.85, Pb0.01).
Non-significant
trend to increased
BMI
Saiman, Anstead,
Mayer-Hamblett et al.
(2010)
Multicentre
randomised
double-blind
placebo-
controlled trial
260 Mean 10.7
(SD 3.17)
P aeruginosa,
non-tuberculous
mycobacteria, and
B cepacia excluded.
b36kg 250mg
3 times weekly;
≥36kg 500mg
3 times weekly
Mean
FEV1%
predicted
98.6%
(SD+/−
15.0)
6months No significant change
in FEV1.
Reduction in pulmonary
exacerbations, hazard ratio
0.50 (95% CI 0.31–0.79,
P=0.003). No significant
effect on IV abx.
0.58kg increase
in body weight
(95% CI 0.14–
1.02, P=0.01)
Abbreviations: FEV1, Forced expiratory volume in one second; FEV1% pred, FEV1 percentage predicted; AZM, azithromycin; IV, intravenous; abx, antibiotics.
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for starting other forms of therapy may have had a worse
outcome, influencing the results. The retrospective design
does not allow direct measures of patient compliance. The
study is unable to comment on long-term efficacy of
azithromycin due to its limited two year follow up period.
Further work needs to be performed to analyse the
longer-term decline in lung function after the initiation of
azithromycin.
Despite a lack of sustained improvement in lung function in
this study, it should be noted that azithromycin may have other
beneficial effects included reduced courses of oral antibiotics
(Clement et al., 2006). In addition, further data from Saiman,
Mayer-Hamblett, Campbell andMarshall (2005) on an early study
(Saiman et al., 2003) showed that reduced exacerbation rates were
not related to improvements in lung function.6. Conclusion
The present study has demonstrated an improvement in lung
function one year after the initiation of azithromycin in patients
not in a clinical trial. However the effects of azithromycin were
not sustained beyond the first year. In addition, azithromycin
did not result in a significant reduction in the number of courses
of intravenous antibiotics. Retrospective studies have major
limitations, but it is clear that further assessment of the long-term
effects of azithromycin is required.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.05.010.References
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